U
DRNA

UBS’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

UBS’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$7K Sell
542
-5,994
-92% -$90.4K ﹤0.01% 9199
2014
Q2 		$148K Buy
+6,536
New +$119K ﹤0.01% 5503

Other funds holding DRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

UBS's DRNA Position: Q3 2014 in Review

UBS reduced its Dicerna Pharmaceuticals, Inc. (DRNA) stake by 92% in Q3 2014, selling an estimated $90.4K and leaving 542 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #9199.

UBS first reported a position in DRNA in Q2 2014 and has held it in 2 quarters since. The position peaked at $148K in Q2 2014. 40 funds tracked by Wall St. Rank hold DRNA as of Q3 2014.

  • UBS held 542 shares of Dicerna Pharmaceuticals, Inc. worth $7K as of Q3 2014.
  • UBS sold 5,994 Dicerna Pharmaceuticals, Inc. shares in Q3 2014, an estimated $90.4K.
  • Dicerna Pharmaceuticals, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9199 holding.
  • UBS first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2014 and has held it in 2 quarters since.
  • UBS's Dicerna Pharmaceuticals, Inc. position peaked at $148K in Q2 2014.
  • 40 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.